
CellCo develops next-generation biologics and biotherapies that aim to create new medicines for complex, data-scarce biological problems. The company combines synthetic biology and artificial intelligence through its CellOS platform, which generates synthetic data to model and engineer biological systems. CellCo is a deep-technology therapeutics company that applies computational modeling, data synthesis, and wet-lab biology to design biologics and biotherapies. The team is in stealth mode and focuses on core technology development and team growth across locations in San Francisco, New York, and Buenos Aires.

CellCo develops next-generation biologics and biotherapies that aim to create new medicines for complex, data-scarce biological problems. The company combines synthetic biology and artificial intelligence through its CellOS platform, which generates synthetic data to model and engineer biological systems. CellCo is a deep-technology therapeutics company that applies computational modeling, data synthesis, and wet-lab biology to design biologics and biotherapies. The team is in stealth mode and focuses on core technology development and team growth across locations in San Francisco, New York, and Buenos Aires.
Headquarters: San Francisco, California, United States
Stage: Seed (Seed round announced Aug 8, 2024)
Focus: Engineering breakthrough medicines using molecular simulation, AI, and synthetic biology
Investors: SOSV; FJ Labs
Founders / CEO: Founders include Carla Gimenez; Franco Goytia (CEO)
Designing next-generation biologics and biotherapies for complex, data-scarce biological problems.
Biotechnology
Investors listed for the round: SOSV; FJ Labs.
“Seed investors include SOSV and FJ Labs.”